Bristol Myers Squibb’s bet on TYK2 continued to pay off Monday, as Sotyktu passed two more Phase 3 tests in psoriatic arthritis, the company announced.
Both pivotal trials met their primary endpoint, with Sotyktu inducing ...
↧